# US 2006/0154904 A1 · Betulinol derivatives as anti-HIV agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154904 A1
- Document ID: US20060154904A1
- Status: Published application
- Kind: A1
- Application number: 11/224,430
- Filed: 2005-09-12
- Published: 2006-07-13
- Earliest claimed: 2004-09-10
- Assignees: Cornell Research Foundation, Inc.
- Inventors: Brij Saxena; Premila Rathnam
- Web page: https://patentgrep.com/patent/US20060154904A1

## CPC

- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

## Claims

### Claim 1

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
R1 is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-Dinitrophenyl Hydrazine, and ═S and
R3 is selected from the group consisting of H and C1-C5 alkyl,
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the subject is a mammal.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound is administered as a tablet in a dosage range of 1 mg-500 mg.

### Claim 4 (depends on 1)

The method according to claim 1, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 5 (depends on 1)

The method according to claim 1, wherein R1 is ═O, R3 is methyl, and n is 4.

### Claim 6 (depends on 1)

The method according to claim 1, wherein R1 is ═O, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 7 (depends on 1)

The method according to claim 1, wherein R1 is —OH, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 8 (depends on 1)

The method according to claim 1, wherein n is 2-8.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said administering is carried out to treat the subject for AIDS.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 11

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
R1 is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S and
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 12 (depends on 11)

The method according to claim 11, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 13 (depends on 11)

The method according to claim 11, wherein R1 is ═O and n is 4.

### Claim 14 (depends on 11)

The method according to claim 11, wherein said administering is carried out to treat the subject for AIDS.

### Claim 15 (depends on 11)

The method according to claim 11, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 16

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
Y1 and Y2 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
R3 is selected from the group consisting of H and C1-C5 alkyl;
Z is H or a protective group; and
n is an integer from 1 to 12,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the subject is a mammal.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the compound is administered as a tablet in a dosage range of 1 mg-500 mg.

### Claim 19 (depends on 16)

The method according to claim 16, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 20 (depends on 16)

The method according to claim 16, wherein Y1 and Y2 are ═O, R3 is methyl, and n is 4.

### Claim 21 (depends on 16)

The method according to claim 16, wherein Y1 and Y2 are ═O, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 22 (depends on 16)

The method according to claim 16, wherein Y1 and Y2 are —OH, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 23 (depends on 16)

The method according to claim 16, wherein n is 2-8.

### Claim 24 (depends on 16)

The method according to claim 16, wherein said administering is carried out to treat the subject for AIDS.

### Claim 25 (depends on 16)

The method according to claim 16, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 26

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
Y1 and Y2 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
Z is H or a protective group; and
n is an integer from 1 to 12,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 27 (depends on 26)

The method according to claim 26, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 28 (depends on 26)

The method according to claim 26, wherein Y1 and Y2 are ═O and n is 4.

### Claim 29 (depends on 26)

The method according to claim 26, wherein said administering is carried out to treat the subject for AIDS.

### Claim 30 (depends on 26)

The method according to claim 26, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 31

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
Y1, Y2, Y3, and Y4 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
R3 is selected from the group consisting of H and C1-C5 alkyl;
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the subject is a mammal.

### Claim 33 (depends on 31)

The method according to claim 31, wherein the compound is administered as a tablet in a dosage range of 1 mg-500 mg.

### Claim 34 (depends on 31)

The method according to claim 31, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 35 (depends on 31)

The method according to claim 31, wherein Y1, Y2, Y3, and Y4 are ═O, R3 is methyl, and n is 4.

### Claim 36 (depends on 31)

The method according to claim 31, wherein Y1, Y2, Y3, and Y4 are ═O, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 37 (depends on 31)

The method according to claim 31, wherein Y1, Y2, Y3, and Y4 are —OH, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 38 (depends on 31)

The method according to claim 31, wherein n is 2-8.

### Claim 39 (depends on 31)

The method according to claim 31, wherein said administering is carried out to treat the subject for AIDS.

### Claim 40 (depends on 31)

The method according to claim 31, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 41

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
Y1, Y2, Y3, and Y4 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 42 (depends on 41)

The method according to claim 41, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 43 (depends on 41)

The method according to claim 41, wherein Y1, Y2, Y3, and Y4 are ═O and n is 4.

### Claim 44 (depends on 41)

The method according to claim 41, wherein said administering is carried out to treat the subject for AIDS.

### Claim 45 (depends on 41)

The method according to claim 41, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 46

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
* is a binding site;
Q is BA, a leaving group, or H;
R3 is H or C1-C5 alkyl;
n is an integer from 1 to 12; and
m is an integer from 1 to 6,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the subject is a mammal.

### Claim 48 (depends on 46)

The method according to claim 46, wherein the compound is administered as a tablet in a dosage range of 1 mg-500 mg.

### Claim 49 (depends on 46)

The method according to claim 46, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 50 (depends on 46)

The method according to claim 46, wherein Y is ═O, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 51 (depends on 46)

The method according to claim 46, wherein Y is —OH, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 52 (depends on 46)

The method according to claim 46, wherein n is 2-8.

### Claim 53 (depends on 46)

The method according to claim 46, wherein said administering is carried out to treat the subject for AIDS.

### Claim 54 (depends on 46)

The method according to claim 46, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 55

A method of treating HIV-1 infection in a subject, said method comprising:
administering to a subject with HIV-1 infection a therapeutically effective amount of a compound having the formula
wherein
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
* is a binding site;
Q is BA, a leaving group, or H;
n is an integer from 1 to 12; and
m is an integer from 1 to 6,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

### Claim 56 (depends on 55)

The method according to claim 55, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 57 (depends on 55)

The method according to claim 55, wherein Y is ═O, n is 5, and m=4.

### Claim 58 (depends on 55)

The method according to claim 55, wherein said administering is carried out to treat the subject for AIDS.

### Claim 59 (depends on 55)

The method according to claim 55, wherein said administering is carried out to prevent AIDS in the subject infected with HIV-1.

### Claim 60

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
R1 is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S and
R3 is selected from the group consisting of H and C1-C5 alkyl,
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 61 (depends on 60)

The method according to claim 60, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 62 (depends on 60)

The method according to claim 60, wherein R1 is ═O, R3 is methyl, and n=4.

### Claim 63 (depends on 60)

The method according to claim 60, wherein R1 is ═O, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 64 (depends on 60)

The method according to claim 60, wherein R1 is —OH, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 65 (depends on 60)

The method according to claim 60, wherein n is 2-8.

### Claim 66

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
R1 is selected from the group consisting of —CH3, ═O, —OH, OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S and
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 67 (depends on 66)

The method according to claim 66, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 68 (depends on 66)

The method according to claim 66, wherein R1 is ═O and n is 4.

### Claim 69

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
Y1 and Y2 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
R3 is selected from the group consisting of H and C1-C5 alkyl;
Z is H or a protective group; and
n is an integer from 1 to 12,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 70 (depends on 69)

The method according to claim 69, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 71 (depends on 69)

The method according to claim 69, wherein Y1 and Y2 are ═O, R3 is methyl, and n is 4.

### Claim 72 (depends on 69)

The method according to claim 69, wherein Y1 and Y2 are ═O, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 73 (depends on 69)

The method according to claim 69, wherein Y1 and Y2 are —OH, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 74 (depends on 69)

The method according to claim 69, wherein n is 2-8.

### Claim 75

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
Y1 and Y2 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
Z is H or a protective group; and
n is an integer from 1 to 12,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 76 (depends on 75)

The method according to claim 75, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 77 (depends on 75)

The method according to claim 75, wherein Y1 and Y2 are ═O and n=4.

### Claim 78

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
Y1, Y2, Y3, and Y4 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
R3 is selected from the group consisting of H and C1-C5 alkyl;
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 79 (depends on 78)

The method according to claim 78, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 80 (depends on 78)

The method according to claim 78, wherein Y1, Y2, Y3, and Y4 are ═O, R3 is methyl, and n=4.

### Claim 81 (depends on 78)

The method according to claim 78, wherein Y1, Y2, Y3, and Y4 are ═O, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 82 (depends on 78)

The method according to claim 78, wherein Y1, Y2, Y3, and Y4 are —OH, R3 is H, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 83 (depends on 78)

The method according to claim 78, wherein n is 2-8.

### Claim 84

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
Y1, Y2, Y3, and Y4 are independently selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
n is an integer from 1 to 12; and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 85 (depends on 84)

The method according to claim 84, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 86 (depends on 84)

The method according to claim 84, wherein Y1, Y2, Y3, and Y4 are ═O and n=4.

### Claim 87

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
* is a binding site;
Q is BA, a leaving group, or H;
R3 is H or C1-C5 alkyl;
n is an integer from 1 to 12; and
m is an integer from 1 to 6,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 88 (depends on 87)

The method according to claim 87, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 89 (depends on 87)

The method according to claim 87, wherein Y is ═O, n is 5, and m is 3.

### Claim 90 (depends on 87)

The method according to claim 87, wherein Y is ═O, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 91 (depends on 87)

The method according to claim 87, wherein Y is —OH, Z is —C(═O)—O-t-buty 1, and n is 4.

### Claim 92 (depends on 87)

The method according to claim 87, wherein n is 2-8.

### Claim 93

A method of inhibiting HIV-1 activity in a cell, said method comprising:
providing a cell infected with HIV-1 and
contacting the cell with a compound having the formula
wherein
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-DNP, and ═S;
* is a binding site;
Q is BA, a leaving group, or H;
n is an integer from 1 to 12; and
m is an integer from 1 to 6,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

### Claim 94 (depends on 93)

The method according to claim 93, wherein Z is selected from the group consisting of butyloxycarbonyl and carbobenzoxy.

### Claim 95 (depends on 93)

The method according to claim 93, wherein Y is ═O, n=5, and m=4.

### Claim 96

A method of treating and/or inhibiting HIV-1 infection in a human, which comprises:
administering to a human infected with HIV-1 a therapeutically effective amount of a compound having the formula
wherein
n is an integer from 1 to 12 and
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat and/or inhibit the human for HIV-1 infection.

### Claim 97 (depends on 96)

The method according to claim 96, wherein the compound is administered as a tablet in a dosage range of 1 mg-500 mg.

### Claim 98

A method of treating and/or inhibiting HIV-1 infection in a human, said method comprising:
administering to a human infected with HIV-1 a therapeutically effective amount of a compound having the formula
wherein
Z is H or a protective group,
or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat and/or inhibit the human for HIV-1 infection.

### Claim 99 (depends on 98)

The method according to claim 98, wherein the compound is administered as a tablet in a dosage range of 1 mg-500 mg.

### Claim 100

A method of treating and/or inhibiting HIV-1 infection in a subject, which comprises:
administering to a subject infected with HIV- I a therapeutically effective amount of a compound having the formula:
wherein
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-dinitrophenyl hydrazine, and ═S;
* is a binding site;
X is selected from the group consisting of
each R4 is independently selected from the group consisting of H, CH3, CH2—CH3, NH2 and OH;
Z is H, a protective group, or BA;
n is an integer from 1 to 8;
m is an integer from 1 to 6; and
q is 0 or 1,
or a pharmaceutically acceptable salt thereof.

### Claim 101

A method of treating HIV-1 infection in a subject, which comprises:
administering to a subject infected with HIV-1 a therapeutically effective amount of a compound having the formula:
wherein
W is H, OX, or CH2—OX; and
each X is independently H, a sugar, or BA, and wherein at least 1 X is BA; and
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-dinitrophenyl hydrazine, and ═S; and
* is a binding site,
or a pharmaceutically acceptable salt thereof.

### Claim 102

A method of treating HIV-1 infection in a human, which comprises:
administering to a human infected with HIV-1 a therapeutically effective amount of a compound having the formula:
wherein
W is H, OX, or CH2—OX; and
each X is independently H, a sugar, or BA, and wherein at least 1 X is BA; and
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-dinitrophenyl hydrazine, and ═S; and
* is a binding site,
or a pharmaceutically acceptable salt thereof under conditions effective to treat the human for HIV-1 infection.

### Claim 103

A method of treating HIV-1 infection in a subject, which comprises:
administering to a subject infected with HIV-1 a therapeutically effective amount of a compound having the formula:
wherein
each X is H or a compound of the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —H, —OCH3, —OC(O)CH3, —NNH-2,4-dinitrophenyl hydrazine, and ═S;
* is a binding site,
n is an integer from 1 to 8;
p is 0 or 1; and
m is an integer from 1 to 8;
wherein at least one X is not H, or a pharmaceutically acceptable salt thereof.

### Claim 104

A method of treating HIV-1 infection in a human, which comprises:
administering to a human infected with HIV-1 a therapeutically effective amount of a compound having the formula:
wherein
each X is H or a compound of the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-dinitrophenyl hydrazine, and ═S;
* is a binding site,
n is an integer from 1 to 8;
p is 0 or 1; and
m is an integer from 1 to 8;
wherein at least one X is not H, or a pharmaceutically acceptable salt thereof under conditions effective to treat the human for HIV-1 infection.

### Claim 105

A method of treating HIV-1 infection in a subject, which comprises:
administering to a subject infected with HIV-1 a therapeutically effective amount of a compound having the formula:
wherein
R is a C1 to C5 alkyl;
n is an integer between 5 and 1000; and
BA is a compound having the formula:
wherein
Y is selected from the group consisting of —CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-dinitrophenyl hydrazine, and ═S; and
* is a binding site,
or a pharmaceutically acceptable salt thereof.

### Claim 106

A method of treating HIV-1 infection in a human, which comprises:
administering to a human infected with HIV-1 a therapeutically effective amount of a compound having the formula:
wherein
R is a C1 to C5 alkyl;
n is an integer between 5 and 1000; and
BA is a compound having the formula:
wherein
Y is selected from the group consisting of CH3, ═O, —OH, —OCH3, —OC(O)CH3, —NNH-2,4-dinitrophenyl hydrazine, and ═S; and
* is a binding site,
or a pharmaceutically acceptable salt thereof under conditions effective to treat the human for HIV-1 infection.
